Skip to Content
Upcoming Webinar

Tislelizumab-jsgr: A Unique PD-1 Inhibitor for ESCC and Gastric Cancers

Date: June 18, 2025 | 2:00 PM

Tislelizumab-jsgr is a PD-1 inhibitor with a unique binding profile—designed to support strong and sustained T-cell activation. It’s gaining attention for its role in treating advanced gastrointestinal cancers.

This session’s discussion focused on how tislelizumab fits into the evolving treatment landscape for esophageal squamous cell carcinoma (ESCC) and gastric/gastroesophageal junction adenocarcinoma (G/GEJC)—backed by evidence and clinical insight.

What we’ll cover:

  • What makes tislelizumab different: mechanism of action and clinical relevance
  • RATIONALE 302 & 305 trial data: efficacy and safety in both lines of therapy
  • Biomarker and patient selection strategies
  • Dosing, administration, and management of immune-related adverse events
  • Patient access and support through myBeOne Support™

 

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.